ArticleWorld journal of gastrointestinal oncology2025
Combined detection of P53, Ki67, P504S, and IMP3: Diagnostic implications for gastric cancer and precursor lesions.
Article in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDifferential diagnosis among atypical hyperplasia (AH) (including reparative hyperplasia and intestinal metaplasia), low-grade dysplasia (LGD), high-grade dysplasia (HGD), and adenocarcinoma (AC) in gastric mucosal biopsies is challenging due to histomorphological overlaps, variability in pathological diagnosis consistency, and limited reproducibility.
aimTo evaluate the diagnostic utility of P53, Ki67, P504S, and IMP3 in gastric cancer and its precancerous lesions, focusing on their effectiveness in distinguishing AH, LGD, HGD, and AC.
methodsFrom January 2018 to September 2020, a total of 185 gastric mucosal biopsy specimens were analyzed according to the pathological diagnostic criteria outlined in the World Health Organization Classification of Digestive System Tumors (2019). The specimens were categorized into four groups: AH, LGD, HGD, and AC. Immunohistochemistry was employed to assess the expression status of P53, Ki67, P504S, and IMP3. Intergroup comparisons were performed using the
resultsThe expression rate of P504S was highest in the LGD group (53.3%, 16/30), while IMP3 expression was highest in the AC group (41.9%, 26/62), followed by the HGD group (33.3%). Significant differences in P504S and IMP3 expression levels were observed among the four lesion groups (
conclusionP504S is highly expressed in LGD and is associated with the Ki67 "polarity" expression pattern. IMP3 is highly expressed in HGD/AC and is correlated with the
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.